🔎 Trials Near Me

Domov › Akutna mieločna levkemija › North Carolina › Winston-Salem

Klinične študije za Akutna mieločna levkemija v Winston-Salem, NC

18 študij za Akutna mieločna levkemija išče udeležence na lokacijah v Winston-Salem in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Vključevanje udeležencevFaza 2
  • Novant Health Forsyth Medical Center, Winston-Salem
  • Wake Forest University Health Sciences, Winston-Salem
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT05564390

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Vključevanje udeležencevFaza 1
  • Wake Forest University Health Sciences, Winston-Salem
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Novant Health Forsyth Medical Center, Winston-Salem
  • Wake Forest University Health Sciences, Winston-Salem
Starost 18–59 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Vključevanje udeležencevFaza 3
  • Novant Health Winston Salem, Winston-Salem
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06852222

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Wake Forest University Health Sciences, Winston-Salem
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Wake Forest University Health Sciences, Winston-Salem
Starost 18–59 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Wake Forest University Health Sciences, Winston-Salem
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Vključevanje udeležencevFaza 3
  • Wake Forest University Health Sciences, Winston-Salem
6 Months – 21 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT04293562

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Vključevanje udeležencevFaza 2
  • Atrium Health Wake Forest Baptist Medical Center, Winston-Salem
Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT07471841

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Vključevanje udeležencevFaza 1
  • Wake Forest University Health Sciences, Winston-Salem
Starost 18–75 · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT05886049

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

Vključevanje udeležencevOpazovalna študija
  • Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Starost 18 in več · Vsi spoli · Posodobljeno 24. jul. 2026 · NCT06580106

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

Vključevanje udeležencev
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Starost 18–64 · Vsi spoli · Posodobljeno 23. jul. 2026 · NCT06945042

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Vključevanje udeležencevFaza 2
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Starost 18 in več · Vsi spoli · Posodobljeno 10. jul. 2026 · NCT05442216

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Vključevanje udeležencev
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem
Starost 60 in več · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT06697600

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Vključevanje udeležencevOpazovalna študija
  • Wake Forest Baptist Health, Winston-Salem
Starost 18–120 · Vsi spoli · Posodobljeno 13. apr. 2026 · NCT01890486

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Vključevanje udeležencevFaza 1/2
  • Atrium Wake Forest Baptist Medical Center, Winston-Salem
Starost 12 in več · Vsi spoli · Posodobljeno 24. mar. 2026 · NCT04988555

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Vključevanje udeležencevFaza 1/2
  • Novant Health Cancer Institute, Winston-Salem
Starost 18 in več · Vsi spoli · Posodobljeno 10. dec. 2025 · NCT06680752

Študije za Akutna mieločna levkemija v drugih mestih

Druge študije v Winston-Salem

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.